Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Meridia Risk Management Program Sufficiently Addresses Safety Issues, FDA Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency denies Public Citizen petition to remove Abbott’s weight loss drug Meridia (sibutramine) from the market.

You may also be interested in...



Public Citizen Re-Petitions FDA To Withdraw Obesity Drug Meridia

Public Citizen has renewed its call for FDA to ban Abbott's obesity drug Meridia (sibutramine) following the release of preliminary results of a 10,000 patient study that showed the drug had a slightly higher rate of cardiovascular events

Public Citizen Re-Petitions FDA To Withdraw Obesity Drug Meridia

Public Citizen has renewed its call for FDA to ban Abbott's obesity drug Meridia (sibutramine) following the release of preliminary results of a 10,000 patient study that showed the drug had a slightly higher rate of cardiovascular events

Meridia Pediatric Adverse Events Will Get Continued Monitoring

FDA notes that only one pediatric adverse case report was recorded and additional surveillance is necessary for a more meaningful analysis.

Related Content

Topics

UsernamePublicRestriction

Register

PS062739

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel